The provided text consists of excerpts from a Merck & Co., Inc. Third-Quarter 2025 Sales and Earnings conference call presentation, outlining the company's performance, strategy, and pipeline updates. The presentation highlights $17.3 billion in worldwide sales for the quarter, driven by strong growth in Oncology, particularly KEYTRUDA ($8.1 billion in sales), and Animal Health. Management discusses the company's focus on innovation and growth, citing a pipeline with around 80 Phase 3 trials and a strategic acquisition, Verona Pharma, for a new COPD treatment. The report also details progress across various therapeutic areas, including Immunology, Ophthalmology, and Cardiopulmonary diseases, along with an updated 2025 financial outlook predicting non-GAAP EPS between $8.93 and $8.98.
No persons identified in this episode.
This episode hasn't been transcribed yet
Help us prioritize this episode for transcription by upvoting it.
Popular episodes get transcribed faster
Other recent transcribed episodes
Transcribed and ready to explore now
3ª PARTE | 17 DIC 2025 | EL PARTIDAZO DE COPE
01 Jan 1970
El Partidazo de COPE
13:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
12:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
10:00H | 21 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
13:00H | 20 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana
12:00H | 20 DIC 2025 | Fin de Semana
01 Jan 1970
Fin de Semana